Comprehensive medication guide to Cibinqo including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$500/month depending on specialty-tier copay; prior authorization required on virtually all commercial plans. Eligible commercially insured patients may pay $0/month with the Pfizer Copay Savings Card (max $15,000/year benefit). Medicare Part D covers Cibinqo with a $2,100 annual OOP cap in 2026.
Estimated Cash Pricing
Approximately $7,128 retail for 30 tablets of Cibinqo 100 mg; around $6,032 for 200 mg — no generic is available. With SingleCare or GoodRx, costs may reduce to approximately $5,517 per 30-day supply.
Medfinder Findability Score
45/100
On this page
Cibinqo is the brand name for abrocitinib, an oral prescription medication manufactured by Pfizer Inc. It belongs to the Janus kinase (JAK) inhibitor drug class — specifically, it is a selective JAK1 inhibitor. Cibinqo was FDA-approved on January 14, 2022, making it one of the newer oral treatments for moderate-to-severe atopic dermatitis (eczema) in the United States.
Cibinqo is indicated for adults and adolescents 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. It is taken as a once-daily oral tablet in 50 mg, 100 mg, or 200 mg doses.
Unlike biologic injections such as Dupixent (dupilumab), Cibinqo is a synthetic small molecule taken orally — an important differentiator for patients who prefer not to self-inject. It is not a controlled substance and requires no special prescribing authority beyond a standard prescription license.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Atopic dermatitis is driven by an overactive immune system that releases inflammatory cytokines — chemical messengers including IL-4, IL-13, IL-31, IL-22, and TSLP — that cause skin inflammation, itch, and barrier dysfunction. These cytokines rely on the JAK-STAT signaling pathway inside cells to transmit their inflammatory effects.
Cibinqo (abrocitinib) works by reversibly blocking the JAK1 enzyme at its ATP binding site, preventing JAK1 from activating the STAT proteins that carry inflammatory signals to the cell nucleus. By inhibiting JAK1, Cibinqo simultaneously disrupts signaling from multiple inflammatory cytokines at once, reducing skin inflammation and itch. In laboratory testing, abrocitinib is 28-fold more selective for JAK1 over JAK2 and more than 340-fold selective over JAK3.
One notable feature of Cibinqo's mechanism is rapid itch relief. By blocking IL-31 signaling — known as the "itch cytokine" — many patients report significant reduction in pruritus within 2 weeks of starting treatment. Skin clearance continues to improve over 12 weeks of treatment, with clinical trials showing approximately 47.5% of patients on 200 mg achieving clear or almost clear skin (IGA 0/1) at 12 weeks.
50 mg — tablet
For patients with moderate renal impairment (eGFR 30–59 mL/min), CYP2C19 poor metabolizers, or those on strong CYP2C19 inhibitors
100 mg — tablet
Recommended starting dose for most patients; once daily with or without food
200 mg — tablet
For patients who do not achieve adequate response after 12 weeks on 100 mg; once daily
As of 2026, Cibinqo is not listed on the FDA's official drug shortage database. Pfizer's supply of abrocitinib tablets is stable. However, Cibinqo is a specialty medication distributed exclusively through specialty pharmacy networks — it is not stocked at most retail pharmacies. This means patients cannot simply walk into a CVS or Walgreens and pick it up.
The primary barriers to access are: prior authorization requirements (virtually universal), specialty pharmacy distribution (Accredo, CVS Specialty, Walgreens Specialty), step therapy mandates from many insurance plans, and high cost with no generic available. These systemic barriers can make Cibinqo feel inaccessible even when supply is not the issue.
If you're having trouble locating Cibinqo at a pharmacy near you, medfinder calls pharmacies near you to identify which ones have Cibinqo in stock and can fill your prescription. You provide your medication, dosage, and location — medfinder does the calling and texts you results.
Cibinqo is not a controlled substance and has no DEA scheduling requirements. Any licensed prescriber with standard prescriptive authority can write a prescription for abrocitinib. However, due to its boxed warning, required pre-treatment laboratory screening, and complex prior authorization process, it is most commonly prescribed by specialists with expertise in inflammatory skin conditions.
Common prescriber types include:
Board-certified dermatologists (most common)
Allergists and immunologists
Nurse Practitioners (NPs) working in dermatology or allergy practices
Physician Assistants (PAs) with appropriate prescriptive authority
Primary care physicians with experience managing atopic dermatitis
Telehealth prescribing of Cibinqo is available — since it is not a controlled substance, there are no federal telehealth prescribing restrictions. However, patients will still need baseline laboratory work completed at a local facility before safely initiating therapy. Several telehealth dermatology platforms can facilitate Cibinqo prescribing with appropriate documentation.
No. Cibinqo (abrocitinib) is not a controlled substance and is not scheduled by the DEA. It does not require any special prescribing authority beyond a standard prescription license, and there are no federal restrictions on prescribing it via telehealth. Any licensed prescriber — including nurse practitioners and physician assistants with prescriptive authority — can write a Cibinqo prescription.
While Cibinqo is not a controlled substance, it does require close medical supervision due to its boxed warning for serious infections, malignancy, major cardiovascular events, and thrombosis. Pre-treatment laboratory screening (TB test, hepatitis screen, CBC, lipid panel, renal function) is required before starting therapy, and ongoing monitoring during treatment is essential.
The most frequently reported side effects in Phase 3 clinical trials include:
Nasopharyngitis (runny nose, sore throat)
Nausea (often early and mild; may improve with food)
Headache
Herpes simplex flares (cold sores, oral/genital herpes)
Increased blood creatine phosphokinase (CPK)
Dizziness, fatigue, acne, vomiting
Urinary tract infections
Hypertension (elevated blood pressure)
Transient thrombocytopenia (low platelets, typically within first 24 days)
Serious infections: herpes zoster (shingles), pneumonia, tuberculosis, invasive fungal infections
Malignancy (lymphoma and other cancers)
Major adverse cardiovascular events (heart attack, stroke)
Thrombosis (blood clots: DVT, pulmonary embolism)
Retinal detachment (reported in clinical trials)
Know what you need? Skip the search.
Dupixent (dupilumab)
Injectable biologic (IL-4/IL-13 inhibitor) given every 2 weeks; no boxed warning; first-line biologic for moderate-to-severe AD; approved for ages 6 months and older
Rinvoq (upadacitinib)
Oral once-daily JAK1 inhibitor (AbbVie); most similar to Cibinqo; carries same boxed warning; available in 15 mg and 30 mg doses; approved for ages 12+
Adbry (tralokinumab)
Injectable IL-13 biologic; given every 2 weeks with option to reduce to monthly; no boxed warning; approved for ages 12+
Ebglyss (lebrikizumab)
Injectable IL-13 biologic (Eli Lilly); monthly maintenance dosing option; no boxed warning; approved for ages 12+
Prefer Cibinqo? We can find it.
Clopidogrel (Plavix) and antiplatelet drugs
majorContraindicated during the first 3 months of Cibinqo treatment due to additive platelet suppression and bleeding risk. Low-dose aspirin (≤81 mg/day) is acceptable.
Strong CYP2C19 inhibitors (fluvoxamine, omeprazole, fluconazole)
majorSignificantly increase abrocitinib blood levels — dose reduction to 50 mg once daily required.
Strong CYP3A4 inducers (rifampin, carbamazepine, St. John's Wort)
majorReduce abrocitinib exposure, potentially decreasing effectiveness. Avoid if possible.
Other JAK inhibitors (upadacitinib, baricitinib, tofacitinib)
majorNot recommended in combination — significantly increases risk of serious infections and other adverse effects.
Biologic immunomodulators (dupilumab, tralokinumab)
majorNot recommended in combination due to additive immune suppression and infection risk.
Systemic immunosuppressants (cyclosporine, methotrexate)
moderateNot recommended in combination; significantly increases infection risk.
P-gp substrates with narrow therapeutic index (digoxin)
moderateCibinqo inhibits P-gp transporter — monitor levels and adjust doses of co-administered P-gp substrates as needed.
Cibinqo (abrocitinib) represents an important advancement in the treatment of moderate-to-severe atopic dermatitis — offering patients who have not responded to biologics or other systemic therapies an effective oral option. Its rapid onset of itch relief (often within 2 weeks) and once-daily oral dosing make it a clinically meaningful choice for patients with significant, refractory disease.
The primary challenges with Cibinqo are not clinical but logistical: prior authorization requirements, specialty pharmacy distribution, and the high list price of approximately $7,000 per month with no generic available. Fortunately, Pfizer offers robust patient support programs — including a copay card that can bring costs to $0/month for eligible commercially insured patients, a bridge program for those experiencing PA delays, and a patient assistance program for uninsured patients.
If you're prescribed Cibinqo and struggling to find it at a pharmacy near you, medfinder can help. We call pharmacies on your behalf to find which ones can fill your prescription, and text you results — no hold music, no runaround. medfinder covers all medications, not just Cibinqo.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
Real-time availability
Medfinder is actively checking pharmacy inventory for Cibinqo. We don't publish a number until we have enough verified pharmacy checks to be accurate — start a search and our team confirms current availability near you, usually within 24 hours.
ChatGPT
Claude
Gemini